Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Geraldin Romis

Nurse Practitioner San Jose, CA Nurse Practitioner

NPI 1053819961 CMS profile 10676394

746 The Alameda Ste 10, San Jose, CA 95126

Open in the dashboard

General payments

$3,930

132 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Geraldin Romis of San Jose, CA is reported in the CMS Open Payments database as having received $3,930 across 132 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,610 62
2024 General $1,229 38
2023 General $670 17
2022 General $89 4
2021 General $333 11

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Geraldin Romis
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Geraldin Romis were reported at $1,610. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Geraldin Romis Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $333 $135 $40–$426 $132
2022 $89 $152 $48–$470 $149
2023 $670 $166 $54–$529 $160
2024 $1,229 $173 $55–$556 $164
2025 $1,610 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Regeneron Healthcare Solutions, Inc. $978 31 payments
  2. Genzyme Corporation $348 12 payments
  3. Novartis Pharmaceuticals Corporation $316 10 payments
  4. Incyte Corporation $294 11 payments
  5. AbbVie, Inc. $292 12 payments
  6. Lilly USA, LLC $272 8 payments
  7. Janssen Biotech, Inc. $263 12 payments
  8. Galderma Laboratories, L.P. $220 3 payments
  9. Dermavant Sciences, Inc. $192 6 payments
  10. LEO Pharma Inc. $159 7 payments
  11. Other $595 20 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $3,592 128 payments
  2. Education $338 4 payments
Products named General payments · program years 2021–2025
  1. DUPIXENT Immunology $541 18 payments
  2. DUPIXENT Inflammation And Immunology $500 16 payments
  3. DUPIXENT Immunology And Inflammation $479 15 payments
  4. OPZELURA $294 11 payments
  5. TREMFYA $263 12 payments
  6. VTAMA $214 7 payments
  7. TALTZ $185 7 payments
  8. COSENTYX $180 4 payments
  9. ADBRY $159 7 payments
  10. SKYRIZI $158 6 payments
  11. Other $1,181 42 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

388

Median for Nurse Practitioner: 389

Drug cost

$85,490

Median for Nurse Practitioner: $21,885

Branded share of claims

4.6%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Pen Dupilumab Brand 18 $74,509
Fluocinonide Generic 40 $2,445
Clindamycin Phosphate Generic 38 $2,094
Tacrolimus Generic 15 $1,988
Ketoconazole Generic 79 $1,517
Metronidazole Generic 22 $1,157
Doxycycline Monohydrate Generic 23 $461
Triamcinolone Acetonide Generic 80 $458
Mometasone Furoate Generic 18 $324
Nystatin Generic 11 $184

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 14 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $307
  • GENZYME CORPORATION $106
$412 18 —
VTAMA
  • Dermavant Sciences, Inc. $176
$176 — —
COSENTYX
  • Novartis Pharmaceuticals Corporation $133
$133 — —
ADBRY
  • LEO Pharma Inc. $75
$75 — —
SKYRIZI
  • AbbVie, Inc. $53
$53 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 14 in the dashboard with a free account

Records

132 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record